CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
4.740
-0.210 (-4.24%)
At close: Feb 17, 2026, 4:00 PM EST
4.781
+0.041 (0.86%)
After-hours: Feb 17, 2026, 7:30 PM EST
Company Description
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.
It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Jun 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 223 |
| CEO | Kevin Hykes |
Contact Details
Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States | |
| Phone | 763 416 2840 |
| Website | cvrx.com |
Stock Details
| Ticker Symbol | CVRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1235912 |
| CUSIP Number | 126638105 |
| ISIN Number | US1266381052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kevin Hykes | President, Chief Executive Officer and Director |
| Brent Binkowski | Chief Operating Officer |
| Jonelle R. Burnham | Vice President and General Counsel |
| Tonya A. Austin SPHR | Chief Human Resources Officer |
| Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer |
| Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 8-K | Current Report |
| Jan 12, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 424B5 | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 15, 2025 | EFFECT | Notice of Effectiveness |
| Nov 17, 2025 | DEL AM | Filing |
| Nov 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |